Search alternatives:
significant point » significant amount (Expand Search), significant part (Expand Search), significant event (Expand Search)
point decrease » point increase (Expand Search)
Showing 1 - 20 results of 8,228 for search '(( significant point decrease ) OR ( significantly ((observed decrease) OR (mean decrease)) ))', query time: 0.68s Refine Results
  1. 1
    Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period.

    Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Join-point regression analysis of the statistically significant linear increase in use of antidementia and antipsychotics during the observed time period.

    Join-point regression analysis of the statistically significant linear increase in use of antidementia and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  3. 3
    Join-point regression analysis of the statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period.

    Join-point regression analysis of the statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Join-point regression analysis of the statistically significant linear increase in use of anxiolytics, psychostimulants and noot ropic drugs, sedatives and hypnotics, gabapentinoids during the observed time period.

    Join-point regression analysis of the statistically significant linear increase in use of anxiolytics, psychostimulants and noot ropic drugs, sedatives and hypnotics, gabapentinoid... by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Middle cerebral artery mean flow velocity at three time points.

    Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 19
    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session.

    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

    Published 2025
    Save to List
    Saved in:
  20. 20
    Shuffling identity decreases behavior trajectory uniqueness.

    Shuffling identity decreases behavior trajectory uniqueness. by Catalin Mitelut (5587493)

    Published 2025
    Save to List
    Saved in:

Search Tools: